Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco Ltd. (IVZ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Invesco Ltd.Trade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Invesco Ltd. vs Regeneron Pharmaceuticals Inc — how do they compare? Invesco Ltd. trades at $31.35 (market cap $13.85B), while Regeneron Pharmaceuticals Inc trades at $797.23 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.9× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.74%). Which is the better fit depends on your goals.

IVZREGN
Market Cap
$13.85B$82.06B
Sector
FinancialsHealth
52-Week High
$32.01$812.27
52-Week Low
$20.67$555.51
Enterprise Value
$24.01B$76.77B
Dividend Yield
2.74%0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco Ltd.

Invesco (IVZ) trades at $31.74, near its 52-week high, with a bullish technical signal supported by moving averages. The company reported mixed quarterly earnings but maintains strong operating cash flow of $1.53 billion for 2025. Recent news highlights record assets under management and positive analyst coverage, though profitability metrics show net income margin at -0.93%.

The outlook remains cautiously optimistic with a consensus price target of $32.50, offering modest upside. Key risks include volatile earnings and expense pressures, while institutional interest and dividend payments provide support. Investors should weigh solid cash generation against margin challenges.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.

Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN